PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23063977-3	2012	These findings indicate that MLL-AF9-expressing cells are more sensitive to ATRA and 5-Aza, indicating that different MLL fusion proteins possess different epigenetic properties associated with retinoic acid pathway inactivation.	Azacitidine	85-90	lysine methyltransferase 2A	Homo sapiens	29-32	
26403224-7	2015	The HMGA2 inhibitor netropsin, when combined with demethylating agent 5-azacytidine, upregulated and sustained the expression of CDKN2A, which resulted in growth suppression of KMT2A-AFF1-expressing cell lines.	Azacitidine	70-83	lysine methyltransferase 2A	Homo sapiens	177-182	
22918121-5	2013	In leukemic cells with an MLL fusion gene, the regulatory region for let-7b expression was hypermethylated, and its expression was partially recovered after culturing the cells with the demethylating agent 5-azacitidine.	Azacitidine	206-219	lysine methyltransferase 2A	Homo sapiens	26-29	
28675638-0	2017	Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.	Azacitidine	0-11	lysine methyltransferase 2A	Homo sapiens	75-80	
28675638-5	2017	This report describes the clinical effectiveness of azacitidine for the treatment of infant MLL-r ALL.	Azacitidine	52-63	lysine methyltransferase 2A	Homo sapiens	92-95	
23063977-3	2012	These findings indicate that MLL-AF9-expressing cells are more sensitive to ATRA and 5-Aza, indicating that different MLL fusion proteins possess different epigenetic properties associated with retinoic acid pathway inactivation.	Azacitidine	85-90	lysine methyltransferase 2A	Homo sapiens	118-121